Estimating the effect of influenza vaccines

The Lancet Infectious Diseases

Volumn 12, Issue 1, 2012, Pages 5-6

  Kelly, Heath ^a   Valenciano, Marta ^b  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b EPICONCEPT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

COHORT ANALYSIS; DRUG EFFICACY; HOSPITAL ADMISSION; HUMAN; INFLUENZA; LETTER; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK REDUCTION; SEROLOGY; VIRUS STRAIN;

HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INFLUENZAVIRUS A; INFLUENZAVIRUS B;

EID: 84155172202     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70289-4     Document Type: Letter

References (10)

1. Osterholm MT, Kelley NS, Sommer A, Belongia EA Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2011, published online Oct 26. 10.1016/S1473-3099(11)70246-0.
2. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E Vaccines for preventing influenza in healthy adults (review). Cochrane Database Syst Rev 2010, 7:CD001269.
3. Last JM A dictionary of epidemiology 2001, Oxford University Press, New York. 4th edn.
4. Simonsen L, Taylor RJ, Viboud C, Miller M, Jackson LA Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Inf Dis 2007, 7:658-666.
5. Petrie JG, Ohmit SE, Johnson E, Cross RT, Monto AS Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis 2011, 203:1309-1315.
6. Valenciano M, Kissling E, Cohen J-M, et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med 2011, 8:e1000388.
7. Kelly H, Peck H, Laurie K, Peng N, Nishuria H, Cowling BJ The age-specific cumulative incidence of infection with pandemic influenza H1N1 2009 was similar in various countries prior to vaccination. PLoS One 2011, 6:e21828.
8. Hung IF, To KK, Lee CK, et al. Effect of clinical and virological parameters on the level of neutralising antibody against pandemic influenza A virus H1N1 2009. Clin Inf Dis 2010, 51:274-279.
9. Puig-Barberà J, Arnedo-Pena A, Pardo-Serrano F, et al. Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines to prevent influenza hospitalisations during the autumn 2009 influenza pandemic wave in Castellon, Spain. A test-negative, hospital-based case-control study. Vaccine 2010, 28:7460-7467.
10. Cheng A, Tosombis J, Kelly H, et al. Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: a test-negative case control study. Vaccine 2011, 29:7320-7325.